← Back to Screener
Valion Bio, Inc. Common Stock (VBIO)
Price$0.96
Favorite Metrics
Market Capitalization$2.76M
All Metrics
Revenue Growth (3Y)-14.77%
Cash Flow / Share (Quarterly)$-3.00
Price vs S&P 500 (YTD)-8.59%
Gross Margin (TTM)-58.09%
Net Profit Margin (TTM)-1557.26%
EPS (TTM)$-9.87
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$-9.87
Revenue Growth (5Y)13.18%
EPS (Annual)$-19.68
ROI (Annual)-223.08%
Gross Margin (Annual)0.26%
Net Profit Margin (5Y Avg)-614.40%
Cash / Share (Quarterly)$5.01
Revenue Growth QoQ (YoY)15.87%
ROA (Last FY)-201.46%
Revenue Growth TTM (YoY)81.20%
EBITD / Share (TTM)$-9.32
ROE (5Y Avg)-194.14%
Operating Margin (TTM)-1548.96%
Cash Flow / Share (Annual)$-3.00
P/B Ratio0.11x
Net Income / Employee (Annual)$-108,700
Net Interest Coverage (TTM)-5.11x
ROA (TTM)-173.34%
EPS Incl Extra (Annual)$-19.68
Current Ratio (Annual)20.13x
Quick Ratio (Quarterly)19.60x
3-Month Avg Trading Volume0.37M
Revenue / Employee (TTM)$9,300
P/S Ratio (Annual)3.54x
Asset Turnover (Annual)0.28x
52-Week High$1.21
Operating Margin (5Y Avg)-584.97%
EPS Excl Extra (Annual)$-19.68
Quick Ratio (Annual)19.60x
Total Debt / Equity (Annual)0.27x
Current Ratio (Quarterly)20.13x
Enterprise Value$6.08M
Revenue / Share Growth (5Y)-10.27%
Asset Turnover (TTM)0.11x
Revenue / Employee (Annual)$15,000
Inventory Turnover (Annual)1.45x
Pretax Margin (Annual)-725.00%
Cash / Share (Annual)$5.01
Gross Margin (5Y Avg)2.21%
Net Income / Employee (TTM)$-144,300
ROE (Last FY)-223.08%
Net Interest Coverage (Annual)-2.10x
EPS Basic Excl Extra (Annual)$-19.68
Receivables Turnover (TTM)34.43x
Total Debt / Equity (Quarterly)0.27x
EPS Incl Extra (TTM)$-9.87
Receivables Turnover (Annual)6.42x
ROI (TTM)-202.20%
P/S Ratio (TTM)5.73x
Pretax Margin (5Y Avg)-614.40%
Revenue / Share (Annual)$2.71
Year-to-Date Return-4.95%
5-Day Price Return-8.13%
EPS Normalized (Annual)$-19.68
ROA (5Y Avg)-165.61%
Net Profit Margin (Annual)-725.00%
Month-to-Date Return-2.02%
EBITD / Share (Annual)$-19.69
Operating Margin (Annual)-725.77%
LT Debt / Equity (Annual)0.27x
ROI (5Y Avg)-194.14%
LT Debt / Equity (Quarterly)0.27x
EPS Basic Excl Extra (TTM)$-9.87
P/B Ratio (Annual)1.34x
Inventory Turnover (TTM)2.07x
Pretax Margin (TTM)-1557.26%
Book Value / Share (Annual)$26.33
Beta3.53x
Revenue / Share (TTM)$0.36
ROE (TTM)-202.20%
52-Week Low$0.86
Industry Peers — Electromedical Equipment(30)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
VBIOValion Bio, Inc. Common Stock | 5.73x | 13.18% | -58.09% | -1548.96% | $0.96 |
| MDTMedtronic plc | 2.76x | 3.01% | 65.16% | 17.00% | $76.15 |
| MASIMasimo Corporation | 6.12x | 5.95% | 61.90% | 20.30% | $178.31 |
| LIVNLivaNova PLC Ordinary Shares | 2.84x | 8.24% | 68.04% | 14.09% | $71.86 |
| ITGRInteger Holdings Corporation | 1.61x | 11.55% | 26.81% | 10.98% | $88.12 |
| TMDXTransMedics Group, Inc. Common Stock | 3.87x | 88.21% | 59.92% | 17.93% | $67.84 |
| AXGNAxogen, Inc. Common Stock | 9.93x | 14.93% | 74.31% | -3.49% | $42.06 |
| CNMDCONMED Corporation | 0.81x | 9.77% | 54.59% | 7.46% | $36.76 |
| BLFSBioLife Solutions Inc. | 11.20x | 14.87% | 64.56% | -17.26% | $22.04 |
| INMDInMode Ltd. Ordinary Shares | 2.39x | 12.45% | 78.54% | 23.05% | $13.96 |
| CBLLCeriBell, Inc. Common Stock | 8.59x | — | 87.89% | -65.57% | $20.20 |
About
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.